{"id":2822,"date":"2025-08-18T16:00:22","date_gmt":"2025-08-18T20:00:22","guid":{"rendered":"https:\/\/halopharma.com\/?page_id=2822"},"modified":"2026-07-02T10:19:05","modified_gmt":"2026-07-02T14:19:05","slug":"news","status":"publish","type":"page","link":"https:\/\/halopharma.com\/fr\/who-we-are\/news\/","title":{"rendered":"Actualit\u00e9s et \u00e9v\u00e9nements"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

\u00c9v\u00e9nements \u00e0 venir<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tCPHI Europe\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\n\t\t\n\t\t\tRejoignez-nous\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\tf\u00e9vrier 24, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tContract Pharma\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\n\t\t\n\t\t\tRejoignez-nous\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\n\t\t\tf\u00e9vrier 24, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t<\/div>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

Derni\u00e8res nouvelles<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Halo Pharma Emerges as Standalone CDMO Following Siegfried Acquisition of Noramco Independent CDMO positioned for growth in sterile injectables and other complex drug product formats Over $30 million investment plan underway to establish sterile vial, prefilled syringe, and cartridge manufacturing in Whippany, NJ Lee Karras (previously CEO of Noramco) named Halo Pharma\u2019s CEO to lead next phase of expansion Whippany, NJ \u2013 May 1, 2026 \u2013 Halo Pharma (the \u201cCompany\u201d), a leading CDMO partner to the pharmaceutical industry and previous<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tmai 1, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tApotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceuticals Weston, Florida and Whippany, New Jersey \u2014 April 14, 2026 \u2013 Apotex Corp. today announced that it has secured a strategic sterile filling partnership with Halo Pharmaceuticals through an investment that provides Apotex with access to a significant portion of the overall sterile injectable filling capacity currently being installed and qualified at Halo\u2019s Whippany, New Jersey facility. This access is intended to support Apotex\u2019s sterile injectable manufacturing network and signals<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tavril 14, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tParenteral and Sterile Fill-Finish Development and Manufacturing Trends\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Halo Pharma Executive Chairman Lee Karras says escalating equipment and component costs are the two biggest challenges facing parenteral\/sterile drug product manufacturers.<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tavril 10, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Whippany, NJ \u2013 January 27, 2026 SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The transaction is subject to customary closing conditions and regulatory approvals Halo Pharma, with sites in Whippany, NJ and Mirabel QC, will remain as a stand-alone company with a focus on growth as a drug product contract development and manufacturing organization (CDMO) Lee Karras will become CEO of Halo Pharma after the<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tjanvier 27, 2026\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma Enhances Manufacturing Capabilities with Macro-Pactor Investment\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Whippany, NJ \u2013 December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor\u00ae to be online in Q1 2026 Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor\u00ae, a versatile roller compactor that enhances the company\u2019s ability to manage complex formulations, improve process efficiency, and deliver consistent solid-dose pharmaceutical products.<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\tD\u00e9cembre 16, 2025\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t
\"\"<\/div><\/a>\n\t\t\t\t
Nouvelles<\/div>\n\t\t\t\t
\n\t\t\t\t

\n\t\t\t\n\t\t\t\tHalo Pharma nomme Laurent Malgouyres directeur du site de Mirabel, au Canada.\t\t\t<\/a>\n\t\t<\/h3>\n\t\t\t\t
\n\t\t\t

Whippany, NJ \u2013 October 14, 2025 Malgouyres joins Halo with over 14 years of operational experience in the pharmaceutical industry As site director, he will oversee the operations of the Halo Mirabel cGMP manufacturing site Halo Pharma, a leading CDMO specializing in pharmaceutical development and manufacturing services, has appointed Laurent Malgouyres as Site Director for its cGMP facility in Mirabel, Quebec, Canada. In his new role, Malgouyres will oversee production, quality, and overall site performance. Malgouyres has worked in the<\/p>\n\t\t<\/div>\n\t\t\n\t\t\n\t\t\tEn savoir plus "\u00bb\t\t<\/a>\n\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\n\t\t\t20 octobre 2025\t\t<\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/article>\n\t\t\t\t<\/div>\n\t\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Upcoming Events Latest News<\/p>","protected":false},"author":24,"featured_media":0,"parent":3362,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"class_list":["post-2822","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/2822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=2822"}],"version-history":[{"count":40,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/2822\/revisions"}],"predecessor-version":[{"id":4091,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/2822\/revisions\/4091"}],"up":[{"embeddable":true,"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/pages\/3362"}],"wp:attachment":[{"href":"https:\/\/halopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=2822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}